Infrequent repeat dosing can support a treatment hypothesis without directly measuring every seizure or proving complete control.
An exploratory analysis of an open-label safety study examined diaries from 163 treated patients. A second diazepam nasal-spray dose was recorded for 485 of 3,853 seizure clusters, or 12.6%. Repeat administrations occurred throughout the twenty-four-hour observation window, and fewer than half of patients ever used a second dose.
The study had no untreated or active control group and was not powered for comparative effectiveness. Diaries depend on seizure recognition, instructions and complete reporting. Choosing not to administer another dose is different from objectively documenting no further seizures.
For a rescue-treatment opinion, examine the individual action plan, observed seizure activity, caregiver decisions and administration times. The denominator matters: the proportion of clusters receiving a second dose differs from the proportion of patients ever receiving one. Neither statistic alone proves sustained control in a particular episode.
Source reviewed: Use of second doses of Valtoco diazepam nasal spray across 24 hours after the initial dose for out o (PMC9305147). Forensic applications above are interpretive analysis of the supplied publication.
Related reading: Moschus–Diazepam Rat Microdialysis Findings Do Not Directly Measure Sedative Depth.